Proteomic analysis enables distinction of early- versus advanced-stage lung adenocarcinomas.

Olga KelemenIndira Pla ParadaAniel SanchezMelinda RezeliAttila Marcell SzaszJohan MalmViktoria LaszloHo Jeong KwonBalazs DomeGyorgy Marko-Varga

Published in: Clinical and translational medicine (2020)

Further analysis of these data may provide an insight into the molecular pathways involved in disease etiology and may lead to the identification of biomarker candidates and potential targets for therapy. Our study provides potential diagnostic biomarkers for lung ADC and novel stage-specific drug targets for rational intervention.

Keyphrases

randomized controlled trial
electronic health record
big data
magnetic resonance imaging
diffusion weighted imaging
machine learning
magnetic resonance
diffusion weighted
data analysis
replacement therapy